NCT06344871 Exploratory Study Using a New Head-only PET Scanner / ExploreNeuroLF
| NCT ID | NCT06344871 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Positrigo AG |
| Condition | Brain Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-03-13 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-03-13 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The "NeuroLF prototype" is a small aperture PET scanner. The NeuroLF prototype will be used with patients, which have just finished their regularly scheduled PET examination on a clinical whole body PET system. The radioactive tracer used for this procedure will still be active. This remaining acitivity will be used for an image acquisition with the NeuroLF prototype without the need for an additional radioactive tracer dose. The control intervention is be a brain PET scan as part of standard clinical routine. It will be done immediately before the scan on the NeuroLF prototype.
Eligibility Criteria
Inclusion Criteria: * Capable of giving Informed Consent as documented by signature (Appendix Informed Consent Form). * Ability to sit still in the head-only PET scanner for 15 minutes. * Are scheduled to receive a regular brain PET scan as part of clinical routine. * Male and Female patients 18 years to 80 years of age. Exclusion Criteria: * Contraindications to PET examination, * Patient height smaller than 160 cm or taller than 200 cm, * Patient weight more than 120 kg, * Patient cannot sit upright for at least 15 minutes, * Metal implants in the head, * Pregnant or Breastfeeding women, * Known or suspected non-compliance, drug or alcohol abuse, * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Participation in another study with investigational drug/device within the 30 days preceding and during the present study, * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06344871 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Brain Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06344871 currently recruiting?
Yes, NCT06344871 is actively recruiting participants. Contact the research team at jannis.fischer@positrigo.com for enrollment information.
Where is the NCT06344871 trial being conducted?
This trial is being conducted at Leipzig, Germany, Zurich, Switzerland.
Who is sponsoring the NCT06344871 clinical trial?
NCT06344871 is sponsored by Positrigo AG. The trial plans to enroll 70 participants.